John Marcille

John Marcille

The Northwest Hospital & Medical Center in Seattle, Wash., is doing some interesting things with clinical decision support (CDS), an area that we expect to have an increasingly positive influence on the Bobbsey Twins of health care: quality and cost. Greg Schroedl, MD, the hospital’s chief medical officer, points to order sets that were created for select conditions: “You can deliver similar care to multiple patients over time where hopefully 95 percent of what you do is repeatable and consistent, with some room for customization and variation if indicated for a particular patient.”

An order set for heart failure would, for instance, specify a low-sodium diet, or that the patient be weighed daily to see if he is retaining fluid. This isn’t just theory for hospitals, as the government’s value-based purchasing and readmissions-reduction programs withhold reimbursements if hospitals don’t achieve specific quality metrics and patient satisfaction scores.

Of course, there’s always the matter of physician buy-in. For a number of years some hospital organizations have used evidence-based order sets on paper, says Schroedl, but physician adoption was low and difficult to monitor. “With today’s computerized evidence-based CDS systems, hospitals can offer to physicians order sets of greater value because they are evidence-based and within the context of their established computerized physician order entry workflow. This has greatly increased physician adoption and therefore the value of the hospital’s investment.”

This is the sort of improvement that both hospital and insurer can applaud. “Certainly, health plans want to keep the costs down for their employer clients,” says Schroedl. “They’re interested in positive outcomes for the patient. For hospitals, outcomes are first and foremost. Positive outcomes can also be associated with lower costs if we look at the totality of the care.”

The Bobbsey Twins would be proud.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.